Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Donor lymphocyte infusions

S A Giralt¹, H J Kolb

¹University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

Current Opinion in Oncology

|March 1, 1996

Summary

Donor lymphocyte infusions (DLIs) effectively treat chronic myelogenous leukemia relapse post-transplant but carry risks like graft-versus-host disease. Research aims to improve DLIs for other leukemias and reduce toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Conversion of AML-blasts to leukemia-derived dendritic cells (DCleu) in 'DC-culture-media' shifts correlations of released chemokines with antileukemic T-cell reactions.

Immunobiology·2021

Same author

Lactose drives <i>Enterococcus</i> expansion to promote graft-versus-host disease.

Science (New York, N.Y.)·2019

Same author

Serum Chemokine-release Profiles in AML-patients Might Contribute to Predict the Clinical Course of the Disease.

Immunological investigations·2019

Same author

Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.

Bone marrow transplantation·2017

Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017

Same author

Long term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants.

Bone marrow transplantation·2017

Area of Science:

Immunology
Hematology
Oncology

Background:

Adoptive immunotherapy using donor lymphocyte infusions (DLIs) is increasingly used for relapsed hematologic malignancies post-allogeneic stem cell transplantation.
DLIs offer insights into cell-mediated cytotoxicity, including antigen presentation, immune recognition, and lymphocyte subset functions.

Purpose of the Study:

To evaluate the efficacy and toxicity of donor lymphocyte infusions in treating relapsed hematologic malignancies.
To explore strategies for enhancing DLI effectiveness in non-chronic myelogenous leukemia settings and reducing associated toxicities.

Main Methods:

Review of clinical data on donor lymphocyte infusions for patients with relapsed leukemia after allogeneic bone marrow or stem cell transplantation.
Analysis of factors influencing DLI efficacy, including disease type, timing of infusion, and cell dose.
Investigation of toxicity profiles, primarily graft-versus-host disease and pancytopenia, and proposed mitigation strategies.

Main Results:

Donor lymphocyte infusions demonstrate high efficacy in chronic myelogenous leukemia (CML) relapses, particularly in chronic phase or cytogenetic relapses.
DLIs show limited effectiveness in acute leukemias and other non-CML hematologic disorders.
Significant risks of morbidity and mortality are associated with DLIs, primarily due to graft-versus-host disease and pancytopenia.

Conclusions:

Donor lymphocyte infusions are a valuable, albeit risky, treatment for CML relapse post-transplant.
Strategies such as lower cell doses, earlier infusions, and CD8+ lymphocyte depletion are being explored to mitigate DLI toxicity.
Ongoing research focuses on broadening DLI applicability to non-CML leukemias and refining safety profiles for all indications.

Related Experiment Videos